Lin Pao-Yen, Su Kuan-Pin
Department of Psychiatry, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
J Clin Psychiatry. 2007 Jul;68(7):1056-61. doi: 10.4088/jcp.v68n0712.
Evidence has indicated an association between depression and low dietary intake of omega-3 polyunsaturated fatty acids (PUFAs). However, clinical trials examining the therapeutic benefit of omega-3 PUFAs in depression showed inconsistent results. The goal of this study is to systematically evaluate the antidepressant efficacy of omega-3 PUFAs by using meta-analytic method.
MEDLINE, Embase, and PsycINFO databases were searched from 1966 through August 2006 using the key words (depression OR depressive disorder OR mood disorder) AND (omega-3 OR EPA OR DHA OR poly-unsaturated fatty acid OR fish oil). The search was limited to literature in English and clinical trials.
Ten double-blind, placebo-controlled studies in patients with mood disorders receiving omega-3 PUFAs with the treatment period lasting 4 weeks or longer were included.
Effect size (ES) of each individual study was derived by computing the standardized mean difference. A random-effects model was used to pool the ESs of all included studies.
When pooling the results of 10 included studies (N = 329), we found a significant antidepressant effect of omega-3 PUFAs (ES = 0.61, p = .003). Likewise, omega-3 PUFAs significantly improved depression in patients with clearly defined depression (ES = 0.69, p = .002) or with bipolar disorder (ES = 0.69, p = .0009). The dosage of eicosapentaenoic acid (EPA) did not change the antidepressant efficacy significantly. However, significant heterogeneity among these studies and publication bias were noted.
Although our meta-analysis showed significant antidepressant efficacy of omega-3 PUFAs, it is still premature to validate this finding due to publication bias and heterogeneity. More large-scale, well-controlled trials are needed to find out the favorable target subjects, therapeutic dose of EPA, and the composition of omega-3 PUFAs in treating depression.
有证据表明抑郁症与ω-3多不饱和脂肪酸(PUFAs)的低膳食摄入量之间存在关联。然而,检验ω-3 PUFAs对抑郁症治疗效果的临床试验结果并不一致。本研究的目的是采用荟萃分析方法系统评价ω-3 PUFAs的抗抑郁疗效。
使用关键词(抑郁症或抑郁障碍或心境障碍)和(ω-3或二十碳五烯酸或二十二碳六烯酸或多不饱和脂肪酸或鱼油)检索了1966年至2006年8月的MEDLINE、Embase和PsycINFO数据库。检索仅限于英文文献和临床试验。
纳入了10项双盲、安慰剂对照研究,研究对象为接受ω-3 PUFAs治疗且治疗期持续4周或更长时间的心境障碍患者。
通过计算标准化均数差得出每项独立研究的效应量(ES)。采用随机效应模型汇总所有纳入研究的ES。
汇总10项纳入研究(N = 329)的结果时,我们发现ω-3 PUFAs具有显著的抗抑郁作用(ES = 0.61,p = 0.003)。同样,ω-3 PUFAs能显著改善明确诊断为抑郁症的患者(ES = 0.69,p = 0.002)或双相情感障碍患者的抑郁症状(ES = 0.69,p = 0.0009)。二十碳五烯酸(EPA)的剂量对抗抑郁疗效无显著影响。然而,注意到这些研究之间存在显著异质性和发表偏倚。
尽管我们的荟萃分析显示ω-3 PUFAs具有显著的抗抑郁疗效,但由于发表偏倚和异质性,验证这一发现仍为时过早。需要更多大规模、严格对照的试验来确定治疗抑郁症的合适目标人群、EPA的治疗剂量以及ω-3 PUFAs的组成。